



Overcoming Obstacles, Seizing Opportunities, Curing Cancer

www.ThePrecisionMedicineSummit.com/Boston/2017 | #PrecisionHIT



Realizing the Promise of Precision Medicine, in press (Academic Press)

Lots of skeptics, lots of criticism

- 1. "Physicians already practice personalized/precision medicine"
- 2. Cost is too high
- 3. MD workload would increase exponentially
- 4. Lack of interoperability
- 5. No clinical benefits in the real world





Inzucchi et al. Diabetes Care 2015;38:140-149



Objection 1: personalized medicine vs Personalized Medicine

- Old-time p.m: Switching antibiotics, choosing the best diabetes drug based on protocols—Trial and Error Medicine
- P.M. with capital P addresses numerous interlocking contributing causes/risk factors, how they apply to individual patients
- Imprecise medicine: Looks at large groups in RCT, often addresses intermediate steps in pathogenesis.
- Precision Medicine looks for exact causes--root causes of disease
- Examples: RA typifies imprecise; Fe deficit precision medicine.





TNF = tumor necrosis factor; IL = interleukin







PMI project: 1 million person cohort-- "All of Us Research Program" Designed to detect multiple, interacting risk factors –Identify ROOT CAUSES

- Genomic data
- Diet
- Physical activity level
- Heart rate, respirations via mobile apps and remote sensors
- Medication lists
- Psychosocial stress
- Local weather and air quality
- OTC medication purchases
- Infectious exposure
- Medical history and more



Applying precision medicine requires finding which risk factors affect each patient, and to what degree

Each patient has unique % of risk factors

John Patrick

- 10% genetics
- 50% chronic stress—Stress responders: stress management, cognitive behavioral therapy
- 40% diet—Sodium sensitive hypertension

Mary Smith w/coronary heart disease

- 70% genetic predisposition—Familial hypercholesterolemia
- 10% poor diet,
- 10% chronic stress
- 10% Sedentary lifestyle



To Sum up: We need

A) to determine the best Tx for each contributing cause

B) assessment tools to detect how these contributing risk factors affect each patient

Here's what being done by innovative thinkers using data analytics:





Total score of 146 or above: Talk to your doctor soon about your risk of diabetes, and what preventive steps you should take. Lower scores: At your next checkup, discuss with your doctor how you can keep your risk of diabetes from increasing.

If you haven't had a blood sugar test and you're over age 45 or you have a high body mass index (over 25), talk to your doctor about being tested. Also talk to your doctor if you haven't had your triglyceride levels measured in the last five years.

Model based on data from adults over age 25 who took part in the Diabetes Prevention Program. More information about the research behind this model: http://umhealth.me/diabpre

Sussman JB, Kent DM, Nelson JP et al. BMJ. 2015; 350:h454. http://www.bmj.com/content/350/bmj.h454 COPYRIGHT: University of Michigan {Caveat: Retrospective vs prospective analysis}



New research is pointing way to more personalized care

- Jeremy Sussman et al U of Michigan
- Reanalyzed Diabetes Prevention Program, RCT 3,000+ patients at risk of Type 2 diabetes (Risks: Overweight, GTT, and fasting BG)
 - Intensive Lifestyle modification
 - Metformin
 - Controls



RESULTS:

- Intensive Lifestyle mod: Reduced DM incidence by 58% . So 42% did not.
- Metformin: Reduced incidence of DM by 31% (69% didn't). There was no way to separate responders from non-responders
- DPP researchers suggested applying results to millions of at-risk patients would be a good thing.... REALLY ?

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. N Engl J Med 2002;346:393-403.



- Sussman used predictive analytics to reanalyze raw data and individualize Tx
- Identified 7 key risk factors (out of 17 considered)
 - fasting blood glucose
 - hemoglobin A1c
 - family history of elevated blood glucose
 - blood triglyceride level
 - waist measurement in centimeters
 - waist-to-hip ratio.
 - Height



- Results: "Average reported benefit for metformin was distributed very unevenly across the study population, with the quarter of patients at the highest risk for developing diabetes receiving a dramatic benefit (21.5% absolute reduction in diabetes over three years of treatment) but the remainder of the study population receiving modest or no benefit."
- Take home message: Using this more detailed set of risk factors enabled Sussman to ID individuals more likely to benefit from Tx and those who would not.



Objection 2: Will Precision medicine overwhelm docs with too much data?

That's Wrong Q: How can the workflow of the average clinician be redesigned to accommodate the introduction of precision medicine.

- Seize the opportunity: Redesign for health promotion, comprehensive disease prevention—Ralph Snyderman et al Duke. To Adopt Precision Medicine, Redesign Clinical Care. NEJM Catalyst. Feb 5, 2017. http://catalyst.nejm.org/adopt-precision-medicine-personalized-health/
- Move away from episodic care addressing acute symptoms



- Embrace predictive tools (eg. Sussman)
- Lengthen the duration of office visit; 10 -15 min not enough!
- Give patients more responsibility for their own care (via mobile apps)— J Am Med Inform Assoc (2017) 24 (3): 619-632.
 - Imedicalapps.com—reliable source of clinician-facing and patient facing medical apps.
 - Iprescribeapps.com
 - Iltifat Husain, MD, Editor in chief, Assistant Prof at Wake Forest School of Medicine



Objection 3: The High Cost of Precision Medicine

- Less encouraging scenario
- J Econ Perspectives reviewed 58 cancer drugs, many precision med drugs
 - 1995: additional year of life cost \$54,000
 - 2005: \$139,000
 - 2013: \$207,000
 - ROI: Survival improved by only a few months

Howard DH, Bach PB, Brendt ER et al. Pricing in the Market for Anticancer Drugs. J Economic Perspectives. 2015; 29(1):139-162.



- More positive statistics; Cost effective therapy
- Gleevec (imatinib) for chronic myeloid leukemia
 - Precision approach: addresses key chromosomal translocation close to a root cause
 - 1980 Life expectancy for CML patient: 3.5 yr
 - 2010: 27.3 years
- Similar success story for Herceptin (trastuzumab) for HER2 positive breast cancer



Realizing the Promise of Precision Medicine

The role of patient data, mobile technology, and consumer engagement





Paul Cerrato and John Halamka





Where we are

- EHR 80% adoption of EHRs but with 453 clicks to admit a patient, 140 structured data elements per encounter to support clinical quality measures, 40% of clinicians feel burned out (C+)
- Interoperability we've made reasonable gains with pushing payloads from place to place, but have not built the enabling infrastructure to support pull (C+)
- Patient/family engagement we're making reasonable progress with portals but we need an app that enables true patient stewardship of data (B)
- Big Data analytics many products exist only in Powerpoint (B)
- Cloud/mobile we need to accept that risk can never be zero (B)



Where we need to go

- EHR my wife's thyroid issues and the need for "social" precision medicine
- Patient/Family engagement my recent hypertension diagnosis and "internet of things" precision medicine
- Big Data Analytics my wife's cancer experience and "clinical trial of one" precision medicine



Patient and Provider Mobile Apps

Clinician Apps

ZZPO	DETES	ST, DA	VID 283	-48-4	9 M 2	9 MAY	27,19	86 <u>M</u>	Lists	Tasks P	ation	tSite M	tall Eb	nd Log	noff [
Profile	Pro	Problems/Hx Res			ults Reports			Notes Medications		Orders Sheets			s Hem/Onc C		
										V	sit Su	ummarie	es Oute	ide Clir	ical Sumn
Last Da	y I	ast W	leek	Last	30 Da	ays	Last	90 Day	8 A	II Notes	F	rom Da	te 07/21	/14 To D	
Check All	Date	6	Title		Туре			Autho	r			Status	e	Servic	9
					All		0	All				All		All	
															Check
	11/18	2015	med m testing	acro 12	Initial	note		Ives, D	lavid V. I	ИD		Unsign	bed	Pulmo APG p	nary ractice
	11/17	2015	Med M Testing modifie med	acro 4- id	Prog	ress no	te	lves, E	lavid V. I	D		Unsign	ied	Pulmo APG p	nary ractice
	11/17	2015	Med M Testing	acro	Progress note			lves, E	lavid V. I	ИD		Unsign	ed	Pulmo APG p	nary ractice
	11/17	2015	Med M Testing	acro	Initial	note		lves, D	lavid V. I	ND		Unsign	bed	Pulmo APG p	nary ractice
	11/17	2015	Med M Testing	acro 3	Initial	note		lves, E	lavid V. I	ИD		Unsign	ed	Pulmo APG p	nary ractice
	****	2+00	Anna		8 Tal - 8			A		in .				-	

Inpatient Med Lists

			_
(TET) WANKING	_	_	-
Citer	true?	anari.	-
ZELMARTEST-1, BARBARA 12N	E	t	1
COLORA STREET 1.ELAINE 108		0	
ZZEMAARTEST-1,ERRIN 12m MRN 100-00	E	0	
ZZEMARTEST-1.0ERRY 12H	2	0	
AND THANK TEST-1.HANA THAN	ε	0	
RCF MARTEST-1.JANE COR. 038	ε	0	
REF BERRARTEST 1 JESSE 138		1000	П

eyeRad

PatientSite



Patient Questionnaires



MyICU



Dragon Medical Recorder



Lifelmage Mobile









Population Health and Care Management



John Halamka, MD and Paul Cerrato, MA

Dr Halamka is CIO at Beth Israel Deaconess System Paul Cerrato is Contributing Editor/Writer *Medpage Today*, former Editor *InformationWeek Healthcare*

@jhalamka, @plcerrato

www.ThePrecisionMedicineSummit.com/Boston/2017 | #PrecisionHIT